Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: motor neuron disease gene therapy - Oxford BioMedica

Drug Profile

Research programme: motor neuron disease gene therapy - Oxford BioMedica

Alternative Names: Amyotrophic lateral sclerosis gene therapy - Oxford BioMedica; MoNuDin; OXB-103; SMN-1G; Spinal muscular atrophy gene therapy - Oxford BioMedica

Latest Information Update: 24 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica; The Cleveland Clinic Foundation
  • Developer Oxford BioMedica
  • Class Gene therapies; Spinal muscular atrophy gene therapies
  • Mechanism of Action Gene transference; Survival of motor neuron 1 protein expression stimulants; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Motor neuron disease

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis
  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 24 Oct 2018 Preclinical development in Amyotrophic lateral sclerosis is ongoing in United Kingdom (Oxford BioMedica pipeline, October 2018)
  • 24 Oct 2018 Discontinued - Preclinical for Spinal muscular atrophy in United Kingdom (IM)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in United Kingdom (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top